KYinno Biotechnology Showcases Breakthrough Research at AACR-NCI-EORTC 2023

Share:

Boston, MA – KYinno Biotechnology recently marked its presence at the globally-acclaimed AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Held at the Hynes Convention Center from October 11-15, the conference saw over 1,200 professionals from the world of academia, science, and pharma.

KYinno’s highlight was the unveiling of a poster titled “An in vivo screening platform based on Ba/F3 kinase-engineered cell lines for discovering next-generation kinase inhibitors.” This research addresses the challenge of tumor resistance to kinase inhibitor drugs, emphasizing the potential of Ba/F3, a mouse pro-B cell line.

The presentation showcased over 700 Ba/F3 engineered cell lines, highlighting their stability, reliability, and potential in drug efficacy evaluation. Visual demonstrations accompanied case studies, illustrating the utility of these cell lines in varied scenarios, from murine models to metastasis models.

With this pivotal research, KYinno Biotechnology reinforces its commitment to pioneering advancements in biotechnology and playing a significant role in evolving cancer therapeutics.

Boston, MA – KYinno Biotechnology recently marked its presence at the globally-acclaimed AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Held at the Hynes Convention Center from October 11-15, the conference saw over 1,200 professionals from the world of academia, science, and pharma.

KYinno’s highlight was the unveiling of a poster titled “An in vivo screening platform based on Ba/F3 kinase-engineered cell lines for discovering next-generation kinase inhibitors.” This research addresses the challenge of tumor resistance to kinase inhibitor drugs, emphasizing the potential of Ba/F3, a mouse pro-B cell line.

The presentation showcased over 700 Ba/F3 engineered cell lines, highlighting their stability, reliability, and potential in drug efficacy evaluation. Visual demonstrations accompanied case studies, illustrating the utility of these cell lines in varied scenarios, from murine models to metastasis models.

With this pivotal research, KYinno Biotechnology reinforces its commitment to pioneering advancements in biotechnology and playing a significant role in evolving cancer therapeutics.